EFTR Pengajuan SEC - eFFECTOR Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1828522

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to eFFECTOR Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

July 30, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39866 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified
July 30, 2024	POS AM	As filed with the Securities and Exchange Commission on July 30, 2024. As filed with the Securities and Exchange Commission on July 30, 2024. Registration No. 333-267221 Registration No. 333-272738 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-267221 Form S-3 Registration No. 333-272738 UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, Inc. (Exact name of registrant as sp
July 30, 2024	POS AM	As filed with the Securities and Exchange Commission on July 30, 2024. As filed with the Securities and Exchange Commission on July 30, 2024. Registration No. 333-259751 Registration No. 333-262339 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO: Form S-1 Registration No. 333-259751 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-262339 UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, I
July 30, 2024	S-8 POS	As filed with the Securities and Exchange Commission on July 30, 2024. As filed with the Securities and Exchange Commission on July 30, 2024. Registration No. 333-260688 Registration No. 333-278313 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-8 Registration No. 333-260688 Form S-8 Registration No. 333-278313 UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, Inc. (Exact name of registrant as spec
July 30, 2024	S-8 POS	As filed with the Securities and Exchange Commission on July 30, 2024. As filed with the Securities and Exchange Commission on July 30, 2024. Registration No. 333-260688 Registration No. 333-278313 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-8 Registration No. 333-260688 Form S-8 Registration No. 333-278313 UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, Inc. (Exact name of registrant as spec
July 30, 2024	POS AM	As filed with the Securities and Exchange Commission on July 30, 2024. As filed with the Securities and Exchange Commission on July 30, 2024. Registration No. 333-259751 Registration No. 333-262339 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO: Form S-1 Registration No. 333-259751 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-262339 UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, I
July 30, 2024	POS AM	As filed with the Securities and Exchange Commission on July 30, 2024. As filed with the Securities and Exchange Commission on July 30, 2024. Registration No. 333-267221 Registration No. 333-272738 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-267221 Form S-3 Registration No. 333-272738 UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, Inc. (Exact name of registrant as sp
June 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2024 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 25, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39866 (Commission File Num
June 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2024 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39866 (Commission File Num
June 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
June 24, 2024	EX-99.1	eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq Exhibit 99.1 eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 – eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives
June 14, 2024	EX-3.1	CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF eFFECTOR THERAPEUTICS, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF eFFECTOR THERAPEUTICS, INC. eFFECTOR Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is eFFECTOR Therapeutics, Inc. The original Certifi
June 14, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
May 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2024 eFFECTOR Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 17, 2024	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 3 (To Prospectus dated April 2, 2024) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated April 2, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in this
May 17, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 13, 2024	EX-99.4	POWER OF ATTORNEY EX-99.4 2 d821369dex994.htm EX-99.4 Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederi
May 13, 2024	SC 13D/A	EFTR / eFFECTOR Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-562
May 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commission
May 9, 2024	EX-99.1	eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from register Exhibit 99.1 eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH and REDWOOD CITY, Calif., May 9, 2024 – eFFECTOR Thera
May 9, 2024	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 2 (To Prospectus dated May 9, 2024) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated May 9, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in this pros
May 9, 2024	EX-3.1	At the Market Offering Agreement, dated May 9, 2024, by and between the Company and H.C. Wainwright & Co., LLC Exhibit 3.1 AT THE MARKET OFFERING AGREEMENT May 9, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: eFFECTOR Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in th
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
May 9, 2024	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39866 (Commission File Numbe
May 9, 2024	EX-3.1	At the Market Offering Agreement, dated May 9, 2024, by and between the Company and H.C. Wainwright & Co., LLC Exhibit 3.1 AT THE MARKET OFFERING AGREEMENT May 9, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: eFFECTOR Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in th
May 9, 2024	8-K/A	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39866 (C
May 9, 2024	424B5	$50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267221 Prospectus Supplement (To Prospectus dated September 9, 2022) $50,000,000 Common Stock We have entered into an At the Market Offering Agreement (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospect
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 16, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 4, 2024	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 1 (To Prospectus dated April 2, 2024) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated April 2, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in this
April 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2024 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
April 4, 2024	424B5	$6,762,420 Common Stock 424B5 Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-267221 Prospectus Supplement (To Prospectus dated September 9, 2022) $6,762,420 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated September 9, 2022 and the prospectus supplement, dated August 8, 2023 (collectively, the “Prospectus”), each filed with the Securities and Exchang
March 29, 2024	POS AM	As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. 333-262339 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURI Table of Contents As filed with the Securities and Exchange Commission on March 29, 2024 Registration No.
March 28, 2024	S-8	As filed with the Securities and Exchange Commission on March 28, 2024 S-8 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No.
March 28, 2024	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) eFFECTOR Therapeutics, Inc.
March 26, 2024	EX-97	Policy for Recovery of Erroneously Awarded Compensation EFFECTOR THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION eFFECTOR Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy
March 26, 2024	EX-10.30	General Release of Claims, dated as of February 13, 2024, by and between eFFECTOR and Mayank Gandhi (incorporated by reference to Exhibit 10.30 to the Company’s Form 10-K filed on March 26, 2024). GENERAL RELEASE OF CLAIMS This GENERAL RELEASE OF CLAIMS (this “Release”) is entered into by and between eFFECTOR Therapeutics, Inc.
March 26, 2024	EX-10.18	eFFECTOR Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program. eFFECTOR Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of eFFECTOR Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or
March 26, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39866 eFFECTOR Therap
March 25, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commiss
March 25, 2024	EX-99.1	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC Exhibit 99.1 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in
February 14, 2024	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* eFFECTOR Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28202V108 (CUSIP Number) DECEMBER 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 14, 2024	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / PFIZER INC - SC 13G/A 1 EFFECTOR THERAPEUTICS Passive Investment SC 13G/A 1 effectorschedule13gaexitfi.htm SC 13G/A 1 EFFECTOR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing )* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V207 (CUSIP Number) December 31, 2023 (Da
February 9, 2024	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / SR ONE CAPITAL MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 d766521dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V 108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement
February 9, 2024	EX-99.2	LIMITED POWER OF ATTORNEY EX-99.2 Exhibit 2 LIMITED POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints Sasha Keough, Karen Narolewski-Engel, James Macadam, and Alexander M. Bowling, and each of them singly, as each of the undersigned’s true and lawful attorneys-in-fact with full power and authority as hereinafter described to: 1. execute for and on behalf of each of th
February 9, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT This joint filing agreement (this “Agreement”) is made and entered into as of February 9, 2024, by and among SR One Capital Fund I Aggregator, LP, SR One Capital Partners I, LP, SR One Capital Management, LLC, SR One Co-Invest I, LLC, SR One Co-Invest I Manager, LLC, and Simeon George. The parties to this Agreement hereby agree to prepare jointly and file t
February 5, 2024	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / Altitude Life Science Ventures Fund II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
January 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 eFFECTOR Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
January 26, 2024	EX-99.1	eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SOLANA BEACH, Calif. and REDWOOD CITY, Calif., January 25, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that
January 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2024 eFFECTOR Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
January 26, 2024	EX-4.2	Form of Common Warrant Exhibit 4.2 COMMON STOCK PURCHASE WARRANT EFFECTOR THERAPEUTICS, INC. Warrant Shares: Issue Date: January 29, 2024 Initial Exercise Date: January 29, 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
January 26, 2024	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EFFECTOR THERAPEUTICS, INC. Warrant Shares: Issue Date: January 29, 2024 Initial Exercise Date: January 29, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
January 26, 2024	EX-4.3	Form of Wainwright Warrant Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT EFFECTOR THERAPEUTICS, INC. Warrant Shares: Issue Date: January 29, 2024 Initial Exercise Date: January 29, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein
January 26, 2024	EX-10.1	Form of Securities Purchase Agreement, dated as of January 24, 2024, by and between eFFECTOR and the purchasers named therein. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 24, 2024, between eFFECTOR Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and cond
January 26, 2024	424B5	338,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,150,834 Shares of Common Stock Up to 1,150,834 Shares of Common Stock Underlying the Pre-Funded Warrants Purchase Warrants to Purchase up to 1,488,834 Shares of Common Stock Up to Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267221 PROSPECTUS SUPPLEMENT (To the Prospectus Dated September 9, 2022) 338,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,150,834 Shares of Common Stock Up to 1,150,834 Shares of Common Stock Underlying the Pre-Funded Warrants Purchase Warrants to Purchase up to 1,488,834 Shares of Common Stock Up to 1,48
January 10, 2024	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 15 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
January 10, 2024	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of eFFECTOR Therapeutics, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF eFFECTOR THERAPEUTICS, INC. eFFECTOR Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is eFFECTOR Therapeutics, Inc. The original Certifi
January 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2024 eFFECTOR Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commis
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 eFFECTOR Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commis
January 8, 2024	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 14 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
December 8, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 13 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
December 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2023 eFFECTOR Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
November 28, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 12 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
November 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2023 eFFECTOR Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Comm
November 22, 2023	SC 13D/A	EFTR / eFFECTOR Therapeutics Inc / COLUMN GROUP II, LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) EFFECTOR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) James Evangelista Chief Financial Officer The Column Group II, LP 1 Letterman Drive, Building D, Suite DM-900 San Fra
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2023 eFFECTOR Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Comm
November 13, 2023	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 11 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
November 13, 2023	EX-99.1	eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) EX-99.1 Exhibit 99.1 eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART trial in non-small cell lung canc
September 15, 2023	SC 13D/A	EFTR / eFFECTOR Therapeutics Inc / COLUMN GROUP II, LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) EFFECTOR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) James Evangelista Chief Financial Officer The Column Group II, LP 1 Letterman Drive, Building D, Suite DM-900 San Fra
September 11, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 10 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
September 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2023 eFFECTOR Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 7, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Comm
August 18, 2023	SC 13D/A	EFTR / eFFECTOR Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-562
August 8, 2023	EX-99.1	eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-pos EX-99.1 Exhibit 99.1 eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Positive data update from Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib (ZFA triplet) in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 Cont
August 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commiss
August 8, 2023	424B5	$50,000,000 Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-267221 Prospectus Supplement (To Prospectus dated September 9, 2022) $50,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated September 9, 2022, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-267221) (the “Pr
August 8, 2023	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 9 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
August 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2023 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation or organiz
August 4, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 8 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2023 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
June 23, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 23, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s 8-K filed on June 23, 2023). EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF eFFECTOR THERAPEUTICS, INC. eFFECTOR Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. The name of the Corporation is eFFECTOR Therapeutics, Inc. The original
June 23, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 7 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
June 22, 2023	CORRESP	eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, CA 92075 eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, CA 92075 June 22, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: eFFECTOR Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-272738 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rule
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2023 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 14, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
June 20, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 6 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
June 16, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) eFFECTOR Therapeutics, Inc.
June 16, 2023	S-3	As filed with the Securities and Exchange Commission on June 16, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 16, 2023 Registration No.
June 8, 2023	EX-4.2	Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed on June 8, 2023). EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
June 8, 2023	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on June 8, 2023). EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EFFECTOR THERAPEUTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
June 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 eFFECTOR Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
June 8, 2023	424B5	5,950,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,814,445 Shares of Common Stock Up to 1,814,445 Shares of Common Stock Underlying the Pre-Funded 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267221 PROSPECTUS SUPPLEMENT (To the Prospectus Dated September 9, 2022) 5,950,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,814,445 Shares of Common Stock Up to 1,814,445 Shares of Common Stock Underlying the Pre-Funded Warrants Pursuant to this prospectus supplement and the accompanying prospectus,
June 8, 2023	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 5 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
June 8, 2023	EX-10.1	Form of Securities Purchase Agreement, dated as of June 6, 2023, by and between eFFECTOR and the purchasers named therein. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 6, 2023, between eFFECTOR Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and
June 8, 2023	EX-99.1	eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At- The-Market Under Nasdaq Rules Exhibit 99.1 eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At- The-Market Under Nasdaq Rules SOLANA BEACH and REDWOOD CITY, Calif., June 7, 2023 – eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreement w
June 8, 2023	EX-4.3	Form of Wainwright Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Form 8-K filed on June 8, 2023). EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
May 30, 2023	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K filed on May 30, 2023). EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT EFFECTOR THERAPEUTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
May 30, 2023	EX-4.2	Form of Common Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Form 8-K filed on May 30, 2023). EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
May 30, 2023	424B5	4,700,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 6,750,382 Shares of Common Stock Up to 6,750,382 Shares of Common Stock Underlying the Pre-Funded 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267221 PROSPECTUS SUPPLEMENT (To the Prospectus Dated September 9, 2022) 4,700,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 6,750,382 Shares of Common Stock Up to 6,750,382 Shares of Common Stock Underlying the Pre-Funded Warrants Pursuant to this prospectus supplement and the accompanying prospectus,
May 30, 2023	EX-10.1	Form of Securities Purchase Agreement, dated as of May 26, 2023, by and between eFFECTOR and the purchasers named therein. EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 26, 2023, between eFFECTOR Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and
May 30, 2023	EX-99.1	eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At- The-Market Under Nasdaq Rules EX-99.1 Exhibit 99.1 eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At- The-Market Under Nasdaq Rules SOLANA BEACH and REDWOOD CITY, Calif., May 26, 2023 – eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agr
May 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2023 eFFECTOR Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 30, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 4 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
May 30, 2023	EX-4.3	Form of Wainwright Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Form 8-K filed on May 30, 2023). EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
May 25, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2023 eFFECTOR Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 25, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 3 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
May 19, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 2 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2023 eFFECTOR Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 12, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 9, 2023	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 1 (To Prospectus dated March 16, 2023) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 16, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
May 9, 2023	EX-99.1	eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast EX-99.1 Exhibit 99.1 eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 eFFECTOR Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commission
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
April 27, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 10, 2023	POS AM	As filed with the Securities and Exchange Commission on March 10, 2023 Registration No. 333-262339 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURI Table of Contents As filed with the Securities and Exchange Commission on March 10, 2023 Registration No.
March 8, 2023	EX-10	Employment Agreement, effective as of September 1, 2022, by and between eFFECTOR and Mayank Gandhi. Exhibit 10.34 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and among eFFECTOR Therapeutics, Inc., a Delaware corporation (the “Company”) and Mayank J. Gandhi, M.D. (“Executive”), and shall be effective September 1, 2022 (the “Effective Date”). WHEREAS, the Company and the Executive previously entered into that certain Offer Letter, dated September 1, 2022, (
March 8, 2023	EX-99.1	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs EX-99.1 Exhibit 99.1 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECB
March 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2023 eFFECTOR Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
March 8, 2023	EX-10	Employment Agreement, effective as of August 8, 2022, by and between eFFECTOR and Douglas Warner. Exhibit 10.33 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and among eFFECTOR Therapeutics, Inc., a Delaware corporation (the “Company”) and Douglas Warner, M.D. (“Executive”), and shall be effective August 8, 2022 (the “Effective Date”). WHEREAS, the Company and the Executive previously entered into that certain Offer Letter, dated July 1, 2022, (the “Offer
March 8, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39866 eFFECTOR Therap
March 7, 2023	SC 13G	EFTR / eFFECTOR Therapeutics Inc / Altitude Life Science Ventures Fund II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) August 25, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
March 6, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 16 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 eFFECTOR Therap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39866 (Commission File
February 21, 2023	424B3	eFFECTOR Therapeutics, Inc. 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 15 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used
February 21, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 21, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Comm
February 14, 2023	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / Empyrean Capital Partners, LP - EFFECTOR THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0619sc13ga.htm EFFECTOR THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* eFFECTOR Therapeutics, Inc. (f/k/a Locust Walk Acquisition Corp.) (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) December 31, 2021 (Date of
February 13, 2023	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment SC 13G/A 1 tm236414d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* eFFECTOR Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28202V108 (CUSIP Number) DECEMBER 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
January 5, 2023	EX-99.1	Zotatifin Clinical Data and Corporate Update Participants Agenda • Introductory Remarks • Steve Worland, Ph.D., President & CEO • Zotatifin Oncology Update • Doug Warner, M.D., Chief Medical Officer • Zotatifin COVID Update • Mike Byrnes, Chief Finan Exhibit 99.1 Zotatifin Clinical Data and Corporate Update January 5, 2023 Disclaimer FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the future clinical development of eFFECTOR Therapeutics, Inc.?s (eFFECTOR or the Company) product candidates, in
January 5, 2023	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 14 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
January 5, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2023 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commis
November 7, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
November 7, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
November 7, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 13 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
November 7, 2022	EX-99.1	eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO – - Cohort treating ER+ breast cancer with combination of zotati Exhibit 99.1 eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO ? - Cohort treating ER+ breast cancer with combination of zotatifin, fulvestrant and abemaciclib has been expanded from 7 patients to 18 patients - - Initiated dosing and completed enrollment in second
October 26, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 12 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
October 26, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 eFFECTOR Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39866 (Commission File
September 14, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 11 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in th
September 14, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Com
September 7, 2022	CORRESP	eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, CA 92075 eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, CA 92075 September 7, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: eFFECTOR Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-267221 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General
September 1, 2022	EX-4.4	Form of Indenture. Exhibit 4.4 EFFECTOR THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Esta
September 1, 2022	8-K	Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation or organ
September 1, 2022	EX-1.2	Controlled Equity OfferingSM Sales Agreement Sale Agreement by and between eFFECTOR and Cantor Fitzgerald & Co., dated September 1, 2022. Exhibit 1.2 eFFECTOR THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement September 1, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: eFFECTOR Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follo
September 1, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) eFFECTOR Therapeutics, Inc.
September 1, 2022	S-3	As filed with the Securities and Exchange Commission on September 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2022 Registration No.
September 1, 2022	POS AM	As filed with the Securities and Exchange Commission on September 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2022 Registration No.
September 1, 2022	424B3	eFFECTOR Therapeutics, Inc. 424B3 1 d378846d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 10 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-26233
August 19, 2022	SC 13D/A	EFTR / eFFECTOR Therapeutics, Inc. / US VENTURE PARTNERS X LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) (Amendment No. 1) eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) Dale Holladay c/o U.S. Venture Partners 14
August 19, 2022	SC 13D/A	EFTR / eFFECTOR Therapeutics, Inc. / US VENTURE PARTNERS X LP - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) (Amendment No. 2) eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) Dale Holladay c/o U.S. Venture Partners 14
August 11, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D.
August 11, 2022	SC 13D/A	EFTR / eFFECTOR Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name,
August 11, 2022	EX-99.4	POWER OF ATTORNEY Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings.
August 9, 2022	424B3	eFFECTOR Therapeutics, Inc. 424B3 1 eftrq22022prosupp9.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 9 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-2
August 9, 2022	EX-10.3	Consulting Agreement, dated April 1, 2022, by and between eFFECTOR and Premal Patel, M.D., Ph.D. Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is entered into between Premal Patel, M.D., Ph.D. (?Consultant?), and eFFECTOR Therapeutics, Inc., (the ?Company?), dated as of April 1, 2022 (the ?Effective Date?). WHEREAS, the Consultant was employed by the Company or one of its subsidiaries pursuant to that certain Amended and Restated Employment Agreement, effectiv
August 9, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 12 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in th
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commiss
August 9, 2022	EX-10.2	General Release of Claims, effective as of April 8, 2022, by and between eFFECTOR and Premal Patel, M.D., Ph.D. Exhibit 10.2 GENERAL RELEASE OF CLAIMS This GENERAL RELEASE OF CLAIMS (this ?Release?) is entered into by and between eFFECTOR Therapeutics, Inc. (the ?Company?), and Premal Patel, M.D., Ph.D. (?Employee?), as of the Effective Date (as defined below). WHEREAS, the Company and Employee are parties to that certain Amended and Restated Employment Agreement, effective as of August 25, 2021 (the ?Emplo
August 9, 2022	EX-99.1	eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chi Exhibit 99.1 eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer SAN DIEGO and REDWOOD CITY, Calif., August 9, 2022 ? eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the devel
August 9, 2022	EX-10.4	General Release of Claims, effective as of July 22, 2022, by and between eFFECTOR and Alana McNulty. Exhibit 10.4 GENERAL RELEASE OF CLAIMS This GENERAL RELEASE OF CLAIMS (this ?Release?) is entered into by and between eFFECTOR Therapeutics, Inc. (the ?Company?), and Alana B. McNulty (?Employee?), as of the Effective Date (as defined below). WHEREAS, the Company and Employee are parties to that certain Amended and Restated Employment Agreement, effective as of August 25, 2021 (the ?Employment Agr
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
July 15, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 8 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
July 15, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 11 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in th
July 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
June 10, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 7 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
June 10, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
June 10, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 10 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in th
June 6, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 9 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in thi
June 6, 2022	424B3	eFFECTOR Therapeutics, Inc. 424B3 1 d281498d424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 6 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339
June 6, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 26, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 5 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
May 26, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 26, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 8 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in thi
May 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissio
May 11, 2022	EX-99.1	eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded developmen Exhibit 99.1 eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development of zotatifin SAN DIEGO and REDWOOD CITY, Calif., May 10, 2022 ? eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development
May 10, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 7 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in thi
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
May 10, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 4 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
May 10, 2022	EX-10.1	Third Amendment to Loan and Security Agreement, dated April 28, 2022, by and among eFFECTOR and Oxford Finance LLC. Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of April 28, 2022 (the ?Third Amendment Effective Date?), by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such
April 20, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 20, 2022	DEF 14A	Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commissi
April 4, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 3 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in thi
April 4, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 6 (To Prospectus dated March 21, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated March 21, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in thi
March 28, 2022	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commiss
March 18, 2022	POS AM	As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES A Table of Contents As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.
March 18, 2022	EX-24.2	Power of Attorney (for Kristen Harrington-Smith) Exhibit 24.2 POWER OF ATTORNEY I, the undersigned director of eFFECTOR Therapeutics, Inc., hereby severally constitute and appoint Stephen T. Worland, Ph.D. and Michael Byrnes and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and
March 18, 2022	POS AM	As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. 333-259751 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SEC Table of Contents As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.
March 18, 2022	EX-24.2	Power of Attorney (for Kristen Harrington-Smith) Exhibit 24.2 POWER OF ATTORNEY I, the undersigned director of eFFECTOR Therapeutics, Inc., hereby severally constitute and appoint Stephen T. Worland, Ph.D. and Michael Byrnes and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and
March 16, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commiss
March 16, 2022	EX-99.1	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Exhibit 99.1 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 ? eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year en
March 16, 2022	EX-4.3	Description of Registered Securities. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, eFFECTOR Therapeutics, Inc. (?we,? ?us? and ?our? and the ?Company?) had two classes of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, $0.0001 par value per share
March 16, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39866 eFFECTOR Therap
February 24, 2022	EX-10.1	Joinder and First Amendment to Loan and Security Agreement, dated September 7, 2021, by and among eFFECTOR and Oxford Finance LLC. Exhibit 10.1 JOINDER AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS JOINDER AND FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of September 7, 2021 (the ?First Amendment Effective Date?), by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as
February 24, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 2 (To Prospectus dated February 2, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 2, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in
February 24, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 5 (To Prospectus dated October 5, 2021) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated October 5, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in t
February 24, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Comm
February 24, 2022	EX-10.2	Second Amendment to Loan and Security Agreement, dated February 22, 2022, by and among eFFECTOR and Oxford Finance LLC. Exhibit 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of February 22, 2022 (the ?Second Amendment Effective Date?), by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in
February 16, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 4 (To Prospectus dated October 5, 2021) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated October 5, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in t
February 16, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Comm
February 16, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-262339 Prospectus Supplement No. 1 (To Prospectus dated February 2, 2022) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 2, 2022 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-262339). Capitalized terms used in
February 14, 2022	SC 13G	EFTR / eFFECTOR Therapeutics, Inc. / SR ONE CAPITAL MANAGEMENT, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V 108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 14, 2022	SC 13G	EFTR / eFFECTOR Therapeutics, Inc. / PFIZER INC - SC 13G EFFECTOR THEREAPEUTICS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
February 14, 2022	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* eFFECTOR Therapeutics, Inc. (f/k/a Locust Walk Acquisition Corp.) (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 28202V108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the
February 14, 2022	EX-99.1	AGREEMENT OF JOINT FILING Exhibit 1 AGREEMENT OF JOINT FILING This joint filing agreement (this ?Agreement?) is made and entered into as of January 11, 2022, by and among SR One Capital Fund I Aggregator, LP, SR One Capital Partners I, LP, SR One Capital Management, LLC, SR One Co-Invest I, LLC, SR One Co-Invest Manager I, LLC, and Simeon George.
February 14, 2022	EX-99.1	JOINT FILING AGREEMENT CUSIP No. 28202V108 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: February 14, 2022 PFIZER INC. By: /s/ Su
February 11, 2022	SC 13G	EFTR / eFFECTOR Therapeutics, Inc. / SECTORAL ASSET MANAGEMENT INC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Original Filing)* eFFECTOR Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 28202V108 (CUSIP Number) DECEMBER 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 2, 2022	424B3	eFFECTOR Therapeutics, Inc. Up to 8,133,926 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-262339 PROSPECTUS eFFECTOR Therapeutics, Inc. Up to 8,133,926 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 8,133,926 shares of our common stock by the selling stockholder, Lincoln Park Capital Fund, LLC (?Lincoln Park? or the ?selling stockholder?). The shares of common stock to whi
January 31, 2022	CORRESP	eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, California 92075 January 31, 2022 eFFECTOR Therapeutics, Inc. 142 North Cedros Avenue, Suite B Solana Beach, California 92075 January 31, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jordan Nimitz Re: eFFECTOR Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-262339 Ladies and Gentlemen: In accordance with
January 31, 2022	SC 13G/A	EFTR / eFFECTOR Therapeutics, Inc. / Linden Capital L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
January 25, 2022	S-1	As filed with the Securities and Exchange Commission on January 25, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeut Table of Contents As filed with the Securities and Exchange Commission on January 25, 2022 Registration No.
January 24, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2022 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
January 24, 2022	EX-99.1	Disclaimer FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the future results of operations and Next Generation Targeted Therapy for Cancer Pipeline & Business Update\| January 2022 NON-CONFIDENTIAL Exhibit 99.
January 24, 2022	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 3 (To Prospectus dated October 5, 2021) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated October 5, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in t
January 24, 2022	EX-10.1	Purchase Agreement, dated January 24, 2022, between eFFECTOR and Lincoln Park Capital Fund, LLC. Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of January 24, 2022, is made by and between EFFECTOR THERAPEUTICS, INC., a Delaware Corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subjec
January 24, 2022	EX-10.2	Registration Rights Agreement, dated January 24, 2022, between eFFECTOR and Lincoln Park Capital Fund, LLC. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of January 24, 2022, is made by and between EFFECTOR THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise define
November 8, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2021 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
November 8, 2021	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 2 (To Prospectus dated October 5, 2021) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated October 5, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in t
November 8, 2021	EX-10.1	eFFECTOR Therapeutics, Inc. Non-Employee Director Compensation Program. Exhibit 10.1 eFFECTOR Therapeutics, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the ?Board?) of eFFECTOR Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be made
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc.
November 8, 2021	EX-10.2	Commercial Lease, dated September 29, 2021, by and between North Cedros, LLC and eFFECTOR Therapeutics, Inc. Exhibit 10.2 COMMERCIAL LEASE (142 North Cedros Avenue, Suite B) Section 1. Premises Section 2. Term Section 3. Rental Terms and Security Deposit Section 4. Use Section 5. As-Is Condition ? No Warranty of Fitness Section 6. Improvements/Possession Section 7. Maintenance and Repairs Section 8. Utilities and Taxes Section 9. Insurance Section 10. Default Section 11. Remedies Section 12. Estoppel Cer
November 8, 2021	EX-99.1	eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update ? Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor ? Selected recommended Phase 2 dose (RP2D) of zotatifin for continued development for patients with certain solid
November 2, 2021	S-8	As filed with the Securities and Exchange Commission on November 2, 2021 S-8 1 d420646ds8.htm S-8 As filed with the Securities and Exchange Commission on November 2, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 eFFECTOR Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 85-3306396 (State or other jurisdiction of incorpor
November 1, 2021	424B3	eFFECTOR Therapeutics, Inc. Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259751 Prospectus Supplement No. 1 (To Prospectus dated October 5, 2021) eFFECTOR Therapeutics, Inc. This prospectus supplement updates, amends and supplements the prospectus dated October 5, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259751). Capitalized terms used in t
November 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2021 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of incorporation) (Commi
October 5, 2021	424B3	eFFECTOR Therapeutics, Inc. Up to 47,176,070 Shares of Common Stock Up to 181,667 Warrants Up to 6,015,000 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-259751 PROSPECTUS eFFECTOR Therapeutics, Inc. Up to 47,176,070 Shares of Common Stock Up to 181,667 Warrants Up to 6,015,000 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to: (i) the resale of 28,528,874 shares of common stock, par value $0.0001 per share (the ?Common Stock?), issued in connection with the Bu
October 1, 2021	S-1/A	As filed with the Securities and Exchange Commission on October 1, 2021 Registration No. 333-259751 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF Table of Contents As filed with the Securities and Exchange Commission on October 1, 2021 Registration No.
October 1, 2021	CORRESP	eFFECTOR Therapeutics, Inc. 11120 Roselle Street, Suite A San Diego, California 92121 October 1, 2021 eFFECTOR Therapeutics, Inc. 11120 Roselle Street, Suite A San Diego, California 92121 October 1, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Deanna Virginio Re: eFFECTOR Therapeutics, Inc. Registration Statement on Form S-1 (As Amended) File No. 333-259751 Ladies and Gentlemen: In accordan
September 23, 2021	S-1	Power of Attorney (included on signature page of the initial filing of this Registration Statement) Table of Contents As filed with the Securities and Exchange Commission on September 23, 2021 Registration No.
September 13, 2021	SC 13D	EFTR / eFFECTOR Therapeutics, Inc. / US VENTURE PARTNERS X LP - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) Dale Holladay c/o U.S. Venture Partners 1460 El Camino Real,
September 7, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement.
September 7, 2021	SC 13D	EFTR / eFFECTOR Therapeutics, Inc. / COLUMN GROUP II, LP - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) EFFECTOR THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28202V108 (CUSIP Number) James Evangelista Chief Financial Officer The Column Group II, LP 1 Letterman Drive, Building D, Suite DM-900 San Franci
September 3, 2021	EX-1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares of eFFECTOR Therapeutics, Inc.
September 3, 2021	SC 13D	EFTR / eFFECTOR Therapeutics, Inc. / Abingworth LLP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 eFFECTOR Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28202V108 (CUSIP Number) John Heard Abingworth LLP Princes House 38 Jermyn Street London, England SW1Y 6DN +44 20 7534 1500 (Name, Address and Telephone Nu
August 31, 2021	EX-99.4	eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols Exhibit 99.4 eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW San Diego, CA, August 25, 2021 ? eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective transla
August 31, 2021	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Unless the context otherwise requires, all references in this section to ?we,? ?our,? ?us? or ?eFFECTOR? refer to the business of eFFECTOR Therapeutics, Inc. prior to the consummation of the Business Combination, which will be the business of eFFECTOR following the consummation of the Business Combin
August 31, 2021	EX-99.2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Unless the context otherwise requires, all references in this section to ?we,? ?our,? ?us? or ?eFFECTOR? refer to the business of eFFECTOR Therapeutics, Inc. prior to the consummation of the Business Combination, which will be the business of eFFECTOR following the consummation of the Business Combin
August 31, 2021	EX-99.1	Unaudited condensed financial information of Old eFFECTOR as of and for the three and six months ended June 30, 2021 eFFECTOR Therapeutics, Inc. Index to Financial Statements (Unaudited) Page Condensed Balance Sheets F-2 Condensed Statements of Opera Exhibit 99.1 Unaudited condensed financial information of Old eFFECTOR as of and for the three and six months ended June 30, 2021 eFFECTOR Therapeutics, Inc. Index to Financial Statements (Unaudited) Page Condensed Balance Sheets F-2 Condensed Statements of Operations and Comprehensive Income (Loss) F-3 Condensed Statements of Convertible Preferred Stock and Stockholders? Deficit F-4 Condensed Sta
August 31, 2021	EX-99.1	Unaudited condensed financial information of Old eFFECTOR as of and for the three and six months ended June 30, 2021 eFFECTOR Therapeutics, Inc. Index to Financial Statements (Unaudited) Exhibit 99.1 Unaudited condensed financial information of Old eFFECTOR as of and for the three and six months ended June 30, 2021 eFFECTOR Therapeutics, Inc. Index to Financial Statements (Unaudited) Page Condensed Balance Sheets F-2 Condensed Statements of Operations and Comprehensive Income (Loss) F-3 Condensed Statements of Convertible Preferred Stock and Stockholders? Deficit F-4 Condensed Sta
August 31, 2021	EX-10.18	eFFECTOR Therapeutics, Inc. Non-Employee Director Compensation Program. Exhibit 10.18 EFFECTOR THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of eFFECTOR Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shall be paid or be mad
August 31, 2021	8-K/A	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2021 eFFECTOR Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39866 85-3306396 (State or other jurisdiction of in
August 31, 2021	EX-16.1	Letter from WithumSmith+Brown, PC to the Securities and Exchange Commission. Exhibit 16.1 August 31, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read eFFECTOR Therapeutics, Inc. (formerly known as Locust Walk Acquisition Corp.) statements included under Item 4.01 of its Form 8-K dated August 31, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we
August 31, 2021	EX-99.3	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The combined company after the Business Combination is referred to as the ?Combined Company.? The following unaudited pro forma condensed combined balance sheet of the Combined Company as of June 30, 2021 and the unaudited pro forma condensed combined statements of operations of the Combined Company for the six months ended
August 31, 2021	EX-10.3	Amended and Restated Registration Rights Agreement, dated August 25, 2021, by and among eFFECTOR Therapeutics, Inc., eFFECTOR Therapeutics Operations, Inc., Locust Walk Sponsor, LLC and certain stockholders. Exhibit 10.3 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of August 25, 2021, is made and entered into by and among eFFECTOR Therapeutics, Inc., a Delaware corporation (the ?Company?) (formerly known as Locust Walk Acquisition Corp., a Delaware corporation), Locust Walk Sponsor, LLC, a Delaware limited liabi
August 31, 2021	EX-3.1	Amended and Restated Certificate of Incorporation of eFFECTOR Therapeutics, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LOCUST WALK ACQUISITION CORP. Locust Walk Acquisition Corp. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Locust Walk Acquisition Corp. The Corporation was incorporated under the name
August 31, 2021	EX-3.2	Amended and Restated Bylaws of eFFECTOR Therapeutics, Inc. Exhibit 3.2 Amended and Restated Bylaws of eFFECTOR Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 2 2.5 Notice of Nominations for Election to
August 31, 2021	EX-3.1	Amended and Restated Certificate of Incorporation of eFFECTOR Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed on August 31, 2021). Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LOCUST WALK ACQUISITION CORP. Locust Walk Acquisition Corp. (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: 1. The name of the Corporation is Locust Walk Acquisition Corp. The Corporation was incorporated under the name
August 31, 2021	EX-10.17	eFFECTOR Therapeutics, Inc. 2013 Equity Incentive Plan, as amended, and form of option agreement thereunder. Exhibit 10.17 eFFECTOR THERAPEUTICS, INC. 2013 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better alignin
August 31, 2021	EX-10.17	eFFECTOR Therapeutics, Inc. 2013 Equity Incentive Plan, as amended, and form of option agreement thereunder. Exhibit 10.17 eFFECTOR THERAPEUTICS, INC. 2013 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better alignin
August 31, 2021	EX-10.11	eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Exhibit 10.11 EFFECTOR THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this eFFECTOR Therapeutics, Inc. 2021 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of eFFECTOR Therapeutics, Inc., a Delaware corporation (the ?Company?), and its Designated Subsidiaries in acquiring a stock

EFTR / eFFECTOR Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings